实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (6): 927-930.doi: 10.3969/j.issn.1672-5069.2024.06.032

• 肝癌 • 上一篇    下一篇

肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者血清炎症因子变化及其对远期生存率的影响*

武文华, 蔡芝芳, 李亚萍, 贾晓黎, 党双锁   

  1. 710004 西安市 西安交通大学第二附属医院感染病科
  • 收稿日期:2024-07-04 出版日期:2024-11-10 发布日期:2024-11-07
  • 通讯作者: 党双锁,E-mail:dang212@126.com
  • 作者简介:武文华,女,43岁,医学硕士,主治医师。主要从事肝细胞癌的基础与临床研究。E-mail: wuwenhua812@163.com
  • 基金资助:
    *陕西省重点研发计划项目(编号:2022SF-451);西安交通大学第二附属医院科研基金自由探索项目[编号:2020YJ(ZYTS)236]

Short-term and long-term efficacy of patients with primary liver cancer after hepatic arterial chemoembolization and radiofrequency ablation combination therapy

Wu Wenhua, Cai Zhifang, Li Yaping, et al   

  1. Department of Infectious Disease, Second Affiliated Hospital, Jiaotong University, Xi'an 710004, Shaanxi Province, China
  • Received:2024-07-04 Online:2024-11-10 Published:2024-11-07

摘要: 目的 分析肝动脉栓塞化疗术(TACE)联合射频消融术(RFA)治疗原发性肝癌(PLC)患者血清炎症因子水平变化及其对远期生存率的影响。方法 2016年1月~2018年3月我院诊治的92例PLC患者被随机分为对照组46例和观察组46例,分别接受TACE治疗或TACE联合RFA治疗,随访3年。采用比浊法检测血清超敏C反应蛋白(hs-CRP),采用免疫发光法检测血清白细胞介素-2(IL-2)、IL-6和肿瘤坏死因子-α(TNF-α)水平。结果 观察组近期有效(完全缓解和部分缓解)率为82.6%,显著高于对照组的58.7%(P<0.05);在治疗1年后,观察组44例生存者血清hs-CRP、IL-6和TNF-α水平分别为(5.1±2.0)ng/L、(97.3±12.2)ng/L和(47.8±5.8)pg/mL,显著低于38例对照组【分别为(8.2±1.6)ng/L、(110.3±15.5)ng/L和(53.5±6.8)pg/mL,P<0.05】,而血清IL-2水平为(3.4±0.4)ng/L,显著高于对照组【(3.0±0.5)ng/L,P<0.05】;观察组1 a、2 a和3 a生存率分别为95.7%、84.8%和78.3%,均显著高于对照组的82.6%、65.2%和54.4%(P<0.05)。结论 采取TACE联合RFA治疗PLC患者近期和远期疗效较好,不仅杀灭肿瘤更完全,可能还能改善机体细胞因子分泌。

关键词: 原发性肝癌, 肝动脉栓塞化疗术, 射频消融术, 细胞因子, 治疗

Abstract: Objective The purpose of this study was to investigate short-term and long-term efficacy of patients with primary liver cancer (PLC) after hepatic arterial chemoembolization (TACE) and radiofrequency ablation (RFA) combination therapy. Methods A total of 92 patients with PLC were encountered in our hospital between January 2016 and March 2018, and were randomly divided into control group (n=46) and observation group (n=46), receiving TACE or TACE and RFA combination treatment. All patients were followed-up for three years. Serum high-sensitivity C-reactive protein (hs-CRP), interleukin-2(IL-2), IL-6 and tumor necrosis factor-α(TNF-α) levels were detected. Results Short-term efficacy (complete and partial remission) in the observation group was 82.6%, much higher than 58.7%(P<0.05) in the control; by end of one year after treatmenyt, serum hs-CRP, IL-6 and TNF-α levels in 44 survivals in the observation group were(5.1±2.0)ng/L, (97.3±12.2)ng/L and (47.8±5.8)pg/mL, significantly lower than [(8.2±1.6)ng/L, (110.3±15.5)ng/L and (53.5±6.8)pg/mL, respectively, P<0.05], while serum IL-2 level was (3.4±0.4)ng/L, significantly higher than [(3.0±0.5)ng/L, P<0.05] in 38 survivals in the control group; one-year, two-year and three-year survival rates in the observation group were 95.7%, 84.8% and 78.3%, all much higher than 82.6%, 65.2% and 54.4%(P<0.05) in the control. Conclusion Application of TACE and RFA combination in the treatment of patients with PLC is efficacious, with a satisfactory short-term and long-term survivals, which might improve body immune functions.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Cytokines, Therapy